Skip to main content
    T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $92.21
    +0.83 (+0.91%)

    Market Cap: $3.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TransMedics Group Inc (TMDX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    TransMedics Group (TMDX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, TransMedics Group reported EPS of $0.51, above the $0.27 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(17/30)
    Avg Surprise
    +26.10%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.46
    Range$0.33 - $0.56
    14 analysts
    Revenue Consensus
    $205.69M
    Range$186.10M - $215.57M
    13 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.46
    Range$0.35 - $0.53
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.48-2.5%
    60d ago$0.48-2.5%
    30d ago$0.46+0.1%
    7d ago$0.46+0.1%
    Current$0.46
    Revenue Consensus
    $212.29M
    Range$206.20M - $221.86M
    5 analysts

    Next Report

    TMDX has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 820.0% above the $0.05 reported for the quarter ended Dec 31, 2025.

    TMDX Earnings Call

    The latest TMDX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, TMDX beat 17, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $203.00M, up 41.1% from $143.82M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.51$0.27$0.15 - $0.40+88.89%Beat-22.7%100 up, 2 downNov 5, 2026$203.00M
    Jun 30, 2026$0.44$0.50$0.33 - $0.55-12.00%Miss-52.2%100 up, 4 downAug 4, 2026$189.95M
    Mar 31, 2026$0.30$0.61$0.45 - $0.82-50.82%Miss-57.1%82 up, 3 downMay 5, 2026$173.93M
    Dec 31, 2025$0.05$0.39$0.25 - $0.55-86.94%Miss-73.2%81 up, 0 downFeb 24, 2026$160.76M
    Sep 30, 2025$0.66$0.36$0.29 - $0.51+83.33%Beat+450.0%62 up, 0 downOct 29, 2025$143.82M
    Jun 30, 2025$0.92$0.43$0.34 - $0.59+113.95%Beat+162.9%66 up, 0 downJul 30, 2025$157.37M
    Mar 31, 2025$0.70$0.24$0.12 - $0.34+191.67%Beat+100.0%61 up, 1 downMay 8, 2025$143.54M
    Dec 31, 2024$0.19$0.22N/A-13.64%Miss+58.3%60 up, 4 downFeb 27, 2025$121.62M
    Sep 30, 2024$0.12$0.32$0.03 - $0.39-62.50%Miss+71.4%100 up, 0 downOct 28, 2024$108.76M
    Jun 30, 2024$0.35$0.20$0.11 - $0.29+75.00%BeatN/A80 up, 0 downJul 31, 2024$114.31M
    Mar 31, 2024$0.35$0.01-$0.33 - $0.11N/AN/AN/A50 up, 0 downApr 30, 2024$96.85M
    Dec 31, 2023$0.12-$0.03-$0.08 - $0.08+500.00%BeatN/A40 up, 0 downFeb 26, 2024$81.17M
    Sep 30, 2023$0.07-$0.13-$0.36 - -$0.06+153.85%BeatN/A60 up, 0 downNov 6, 2023$66.43M
    Jun 30, 2023-$0.03-$0.13-$0.27 - -$0.03+76.92%BeatN/A60 up, 0 downAug 3, 2023$52.47M
    Mar 31, 2023-$0.08-$0.24-$0.31 - -$0.14+66.67%BeatN/A51 up, 1 downMay 1, 2023$41.55M
    Dec 31, 2022-$0.21-$0.30-$0.40 - -$0.23+30.00%BeatN/A50 up, 0 downFeb 22, 2023$31.38M
    Sep 30, 2022-$0.25-$0.41-$0.47 - -$0.35+39.02%BeatN/A50 up, 0 downNov 3, 2022$25.68M
    Jun 30, 2022-$0.41-$0.34-$0.41 - -$0.31-20.59%MissN/A50 up, 0 downAug 1, 2022$20.52M
    Mar 31, 2022-$0.38-$0.39-$0.44 - -$0.29+2.56%BeatN/A50 up, 0 downMay 3, 2022$15.88M
    Dec 31, 2021-$0.46-$0.42-$0.45 - -$0.39-9.52%MissN/A5N/AFeb 23, 2022$9.67M
    Sep 30, 2021-$0.47-$0.37-$0.49 - -$0.17-27.03%MissN/A5N/ANov 9, 2021$5.37M
    Jun 30, 2021-$0.39-$0.29-$0.35 - -$0.24-34.48%MissN/A5N/AAug 5, 2021$8.17M
    Mar 31, 2021-$0.29-$0.30-$0.35 - -$0.25+3.33%BeatN/A5N/AMay 4, 2021$7.05M
    Dec 31, 2020-$0.23-$0.25-$0.30 - -$0.17+8.00%BeatN/A5N/AMar 2, 2021$7.63M
    Sep 30, 2020-$0.19-$0.33-$0.37 - -$0.29+42.42%BeatN/A5N/ANov 4, 2020$7.09M
    Jun 30, 2020-$0.36-$0.45-$0.55 - -$0.30+20.00%BeatN/A5N/AAug 5, 2020$3.39M
    Mar 31, 2020-$0.42-$0.40-$0.44 - -$0.38-5.00%MissN/A5N/AMay 6, 2020$7.53M
    Dec 31, 2019-$0.43-$0.40-$0.42 - -$0.37-7.50%MissN/A4N/AMar 2, 2020$6.06M
    Sep 30, 2019-$0.39-$0.45-$0.56 - -$0.37+13.33%BeatN/A4N/ANov 6, 2019$7.21M
    Jun 30, 2019-$0.44-$0.44-$0.47 - -$0.370.00%In lineN/A4N/AAug 7, 2019$5.67M
    Mar 31, 2019-$4.86-$0.98-$1.48 - -$0.48-395.92%MissN/A2N/AMay 2, 2019$4.68M
    Dec 31, 2018-$1.05N/AN/AN/AN/AN/AN/AN/AFeb 27, 2019$3.54M
    Sep 30, 2018-$0.25N/AN/AN/AN/AN/AN/AN/ADec 12, 2018$4.04M
    Last 33 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.33, up 130.8% from the year before. It was -$1.30 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.33+130.8%
    Dec 31, 2024$1.01+1162.5%
    Dec 31, 2023$0.08N/A
    Dec 31, 2022-$1.25N/A
    Dec 31, 2021-$1.61N/A
    Dec 31, 2020-$1.20N/A
    Dec 31, 2019-$6.12N/A
    Dec 31, 2018-$1.30N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,98916
    2026Q2Jun 30, 20267,15316
    2026Q1Mar 31, 20267,36516
    2025Q4Dec 31, 20256,41513
    2025Q3Sep 30, 20258,44317
    2025Q2Jun 30, 20258,50714
    2025Q1Mar 31, 20257,05513
    2024Q4Dec 31, 20246,63610

    2026Q3 Earnings Call

    Opening remarks

    Hannah Jeffrey The Gilmartin Group Representative Thanks, operator. Good afternoon, and welcome to TransMedics' Third Quarter 2026 Earnings Call. I'm joined by our President and CEO, Waleed Hassanein, and our CFO, Fernando Araujo. During this call, we will make forward-looking statements, which are based on how we see things today and are subject to various assumptions. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. Our conference call remarks will also include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures, along with information regarding our use of forward-looking statements, can be found in today's press release and in the presentation slides available on our website. With that, I will hand the call over to Waleed.

    Waleed Hassanein President and CEO Thank you, Hannah. Good afternoon, everyone, and thank you for joining TransMedics' third quarter 2026 earnings call. I'm delighted to be joined today by Fernando Araujo, our new Chief Financial Officer, who will review our third quarter financial results in detail later on this call. TransMedics has built a one-of-a-kind transplant business founded on five foundational assets that are extremely difficult to replicate. At the core is our transformative OCS technology platform, amplified by our clinical organ procurement and donor screening services and enabled by our vertically integrated logistics network and NOP digital assets. Together, they form a single integrated platform with one purpose: to increase the number of organ transplants and improve outcomes for patients worldwide. Our goal is crystal clear: to be the trusted partner to every stakeholder in organ transplantation, committed to growing transplant volumes, maximizing efficiency, and improving post-transplant clinical outcomes. We are very proud of what we've built, but we are not standing still. We firmly believe our best innings are still ahead, and this conviction is why we continue to invest in innovation-driven growth across technology, services, and digital transformation of the transplant ecosystem. I will update you on the progress of these initiatives shortly. Turning to third-quarter results. The third quarter of 2026 was the strongest in TransMedics' history for both revenue and case volume. Third-quarter highlights include total revenue of approximately $203 million, up approximately 41% year-over-year; transplant product revenue of $113 million, up approximately 29% year-over-year; and transplant service revenue of roughly $79 million, up approximately 44% year-over-year. Despite typical third-quarter seasonality, OCS Liver and Heart case volume grew both year-over-year and sequentially, modestly surpassing the all-time high levels we set in the second quarter of 2026. As our near- and midterm growth initiatives begin contributing to case volumes, we fully expect product revenue growth to accelerate further and converge with our service growth rates. TransMedics transplant logistics generated approximately $41 million in revenue, up approximately 50% year-over-year.

    Frequently Asked Questions About TMDX

    When is TransMedics Group's next earnings date?

    TransMedics Group's next earnings report is expected for Feb 22, 2027.

    Did TMDX beat earnings estimates last quarter?

    Yes. TransMedics Group reported EPS of $0.51 for the quarter ended Sep 30, 2026, above the $0.27 estimate, a 88.89% surprise.

    What EPS do analysts expect from TMDX next quarter?

    The consensus EPS estimate for TransMedics Group for the quarter ending Dec 31, 2026 is $0.46 from 14 analysts, with estimates from $0.33 to $0.56.

    How often does TMDX beat earnings estimates?

    TransMedics Group beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +39.31%.